Tag: Ledipasvir

Treatment with Ledipasvir-Sofosbuvir for 12 or 24 weeks in Kidney Transplant Recipients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial Previous data has shown that interferon and ribavirin use in the treatment of chronic hepatitis C virus (HCV) infection in kidney transplant recipients is limited...
1. Sofosbuvir plus ledipasvir was effective in treating chronic hepatitis C virus (HCV) genotype 1 infection in patients who were not candidates for interferon and who suffered viral relapse after prior sofosbuvir-based treatment. Evidence Rating Level: 2 (Good) Study Rundown: Sofosbuvir, an NS5B inhibitor, is an alternative to interferon-based...
Image: PD 1. A single-tablet regimen of ledipasvir and sofosbuvir produced high rates of sustained virologic response among patients with chronic hepatitis C virus genotype 1 infection who had previously failed conventional interferon therapy.  2. No patient discontinued therapy due to an adverse event.  Evidence Rating Level: 1 (Excellent)       Study...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection The current FDA-approved regimen for treatment of Hepatitis C (HCV) genotype 1...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Dolutegravir Plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection Antiretroviral therapy in the treatment of human immunodeficiency virus (HIV) infection has dramatically improved the survival of HIV-positive patients, but traditional...